BBC3 and leukemia: Apparent synergy depends on wild-type TP53, is linked to enhanced activation of p53 by BETi and depends on the expression of at least some p53 target genes, namely BBC3 and NOXA. Regarding the mechanism underlying this enhanced anti-leukemia activity, we eliminated some obvious candidates, such as the binding of p53 to its target genes and the stabilization of p53 target mRNAs.